Conference Paper: Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B

File Download

re01.htm

Links for fulltext
(May Require Subscription)

Publisher Website: 10.1002/hep.24666

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Medicine: Conference papers

Title	Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
Authors	Lai, CL Ahh, SH Lee, KS Um, SH Cho, M Yoon, SK Lee, JW Park, NH Kweon, YO Sohn, JH Lee, J Kim, JA Han, KH Yuen, MF
Keywords	Medical sciences Gastroenterology
Issue Date	2011
Publisher	John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation	The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24 [How to Cite?] DOI: http://dx.doi.org/10.1002/hep.24666
Abstract	BACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for …
Description	This journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011 Poster Presentation
ISSN	0270-9139 2011 Impact Factor: 11.665 2011 SCImago Journal Rankings: 1.278
DOI	http://dx.doi.org/10.1002/hep.24666

DC Field	Value
dc.contributor.author	Lai, CL
dc.contributor.author	Ahh, SH
dc.contributor.author	Lee, KS
dc.contributor.author	Um, SH
dc.contributor.author	Cho, M
dc.contributor.author	Yoon, SK
dc.contributor.author	Lee, JW
dc.contributor.author	Park, NH
dc.contributor.author	Kweon, YO
dc.contributor.author	Sohn, JH
dc.contributor.author	Lee, J
dc.contributor.author	Kim, JA
dc.contributor.author	Han, KH
dc.contributor.author	Yuen, MF
dc.date.accessioned	2012-10-18T08:51:56Z
dc.date.available	2012-10-18T08:51:56Z
dc.date.issued	2011
dc.description.abstract	BACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for …
dc.description.nature	link_to_OA_fulltext
dc.description	This journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011
dc.description	Poster Presentation
dc.description.other	The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24
dc.identifier.citation	The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24 [How to Cite?] DOI: http://dx.doi.org/10.1002/hep.24666
dc.identifier.doi	http://dx.doi.org/10.1002/hep.24666
dc.identifier.epage	1442A
dc.identifier.hkuros	211200
dc.identifier.hkuros	211046
dc.identifier.issn	0270-9139 2011 Impact Factor: 11.665 2011 SCImago Journal Rankings: 1.278
dc.identifier.issue	suppl. 1
dc.identifier.spage	1442A
dc.identifier.uri	http://hdl.handle.net/10722/169370
dc.identifier.volume	54
dc.language	eng
dc.publisher	John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
dc.publisher.place	United States
dc.relation.ispartof	Hepatology
dc.rights	Hepatology. Copyright © John Wiley & Sons, Inc.
dc.subject	Medical sciences
dc.subject	Gastroenterology
dc.title	Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Lai, CL</contributor.author><contributor.author>Ahh, SH</contributor.author><contributor.author>Lee, KS</contributor.author><contributor.author>Um, SH</contributor.author><contributor.author>Cho, M</contributor.author><contributor.author>Yoon, SK</contributor.author><contributor.author>Lee, JW</contributor.author><contributor.author>Park, NH</contributor.author><contributor.author>Kweon, YO</contributor.author><contributor.author>Sohn, JH</contributor.author><contributor.author>Lee, J</contributor.author><contributor.author>Kim, JA</contributor.author><contributor.author>Han, KH</contributor.author><contributor.author>Yuen, MF</contributor.author><date.accessioned>2012-10-18T08:51:56Z</date.accessioned><date.available>2012-10-18T08:51:56Z</date.available><date.issued>2011</date.issued><identifier.citation>The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24</identifier.citation><identifier.issn>0270-9139</identifier.issn><identifier.uri>http://hdl.handle.net/10722/169370</identifier.uri><description>This journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011</description><description>Poster Presentation</description><description.abstract>BACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for &#8230;</description.abstract><language>eng</language><publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www.hepatology.org/</publisher><relation.ispartof>Hepatology</relation.ispartof><rights>Hepatology. Copyright &#169; John Wiley &amp; Sons, Inc.</rights><subject>Medical sciences</subject><subject>Gastroenterology</subject><title>Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B</title><type>Conference_Paper</type><description.nature>link_to_OA_fulltext</description.nature><identifier.doi>10.1002/hep.24666</identifier.doi><identifier.hkuros>211200</identifier.hkuros><identifier.hkuros>211046</identifier.hkuros><identifier.volume>54</identifier.volume><identifier.issue>suppl. 1</identifier.issue><identifier.spage>1442A</identifier.spage><identifier.epage>1442A</identifier.epage><publisher.place>United States</publisher.place><description.other>The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24</description.other><bitstream.url>http://hub.hku.hk/bitstream/10722/169370/1/re01.htm</bitstream.url></item>